MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil

被引：223

作者：

Hirai, Hiroshi ^{[1
]}

Arai, Tsuyoshi ^{[1
]}

Okada, Megumu ^{[2
]}

Nishibata, Toshihide ^{[1
]}

Kobayashi, Makiko ^{[1
]}

Sakai, Naoko ^{[1
]}

Imagaki, Kazuhide ^{[1
]}

Ohtani, Junko ^{[1
]}

Sakai, Takumi ^{[2
]}

Yoshizumi, Takashi ^{[3
]}

Mizuarai, Shinji ^{[1
]}

Iwasawa, Yoshikazu ^{[3
]}

Kotani, Hidehito ^{[1
]}

机构：

[1] Banyu Tsukuba Res Inst, Merck Res Labs, Dept Oncol, Tsukuba, Ibaraki, Japan

[2] Banyu Tsukuba Res Inst, Merck Res Labs, Dept Pharmacol, Tsukuba, Ibaraki, Japan

[3] Banyu Tsukuba Res Inst, Merck Res Labs, Dept Chem, Tsukuba, Ibaraki, Japan

来源：

CANCER BIOLOGY & THERAPY | 2010年 / 9卷 / 07期

关键词：

Wee1; DNA-damaging agents; 5-FU; checkpoint; kinase inhibitor; MK-1775; CANCER CELL-LINES; CHECKPOINT ABROGATION; THYMIDYLATE SYNTHASE; G(2) CHECKPOINT; KINASE; CYCLE; CHK1; PHOSPHORYLATION; SENSITIVITY; MECHANISMS;

D O I：

10.4161/cbt.9.7.11115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

MK-1775 is a potent and selective small molecule Wee1 inhibitor. Previously we have shown that it abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin and cisplatin and enhanced the antitumor efficacy of these agents selectively in p53-deficient tumor cells. MK-1775 is currently in Phase I clinical trial in combination with these anti-cancer drugs. In this study, the effects of MK-1775 on 5-fluorouracil (5-FU) and other DNA-damaging agents with different modes of action were determined. MK-1775 enhanced the cytotoxic effects of 5-FU in p53-deficient human colon cancer cells. MK-1775 inhibited CDC2 Y15 phosphorylation in cells, abrogated DNA damaged checkpoints induced by 5-FU treatment, and caused premature entry of mitosis determined by induction of Histone H3 phosphorylation Enhancement by MK-1775 was specific for p53-deficient cells since this compound did not sensitize p53-wild type human colon cancer cells to 5-FU in vitro. In vivo, MK-1775 potentiated the antitumor efficacy of 5-FU or its prodrug, capecitabine, at tolerable doses. These enhancements were well correlated with inhibition of CDC2 phosphorylation and induction of Histone H3 phosphorylation in tumors. In addition, MK-1775 also potentiated the cytotoxic effects of pemetrexed, doxorubian, camptothecin and mitomyan C in vitro. These studies support the rationale for testing the combination of MK-1775 with various DNA-damaging agents in cancer patients.

引用

页码：514 / 522

页数：9

共 33 条

[1]

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 [J].

Blasina, Alessandra ;

Hallin, Jill ;

Chen, Enhong ;

Arango, Maria Elena ;

Kraynov, Eugenia ;

Grant, Stephan ;

Ninkovic, Sacha ;

Chen, Ping ;

Nichols, Tim ;

O'Connor, Patrick ;

Anderes, Kenna .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) :2394-2404

[2]

Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence [J].

Brody, Jonathan R. ;

Hucl, Tomas ;

Costantino, Christina L. ;

Eshleman, James R. ;

Gallmeier, Eike ;

Zhu, Heng ;

van der Heijden, Michiel S. ;

Winter, Jordan M. ;

Wikiewicz, Agnieszka K. ;

Yeo, Charles J. ;

Kern, Scott E. .

CANCER RESEARCH, 2009, 69 (03) :984-991

[3]

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer [J].

Bucher, N. ;

Britten, C. D. .

BRITISH JOURNAL OF CANCER, 2008, 98 (03) :523-528

[4]

Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil [J].

Calviello, G ;

Di Nicuolo, F ;

Serini, S ;

Piccioni, E ;

Boninsegna, A ;

Maggiano, N ;

Ranelletti, FO ;

Palozza, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) :12-20

[5]

Progress and challenges in the adjuvant treatment of stage II and III colon cancers [J].

Chua, Yu Jo ;

Zalcberg, John R. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) :595-604

[6]

Aurora-B phosphorylates histone H3 at serine28 with regard to the mitotic chromosome condensation [J].

Goto, H ;

Yasui, Y ;

Nigg, EA ;

Inagaki, M .

GENES TO CELLS, 2002, 7 (01) :11-17

[7]

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents [J].

Hirai, Hiroshi ;

Iwasawa, Yoshikazu ;

Okada, Megumu ;

Arai, Tsuyoshi ;

Nishibata, Toshihide ;

Kobayashi, Makiko ;

Kimura, Toshifumi ;

Kaneko, Naoki ;

Ohtani, Junko ;

Yamanaka, Kazunori ;

Itadani, Hiraku ;

Takahashi-Suzuki, Ikuko ;

Fukasawa, Kazuhiro ;

Oki, Hiroko ;

Nambu, Tadahiro ;

Jiang, Jian ;

Sakai, Takumi ;

Arakawa, Hiroharu ;

Sakamoto, Toshihiro ;

Sagara, Takeshi ;

Yoshizumi, Takashi ;

Mizuarai, Shinji ;

Kotani, Hidehito .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (11) :2992-3000

[8]

WEE1+-LIKE GENE IN HUMAN-CELLS [J].

IGARASHI, M ;

NAGATA, A ;

JINNO, S ;

SUTO, K ;

OKAYAMA, H .

NATURE, 1991, 353 (6339) :80-83

[9]

Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells [J].

Jin, P ;

Gu, Y ;

Morgan, DO .

JOURNAL OF CELL BIOLOGY, 1996, 134 (04) :963-970

[10]

Kawabe T, 2004, MOL CANCER THER, V3, P513

← 1 2 3 4 →